Arca
Skip to content
Tools
Tools

DNA

Nucleic acid in Human immunodeficiency virus 2 that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Lamivudine

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        LamivudineBoxed warningApprovedViiV HealthcareSmall moleculeInhibitorDNA inhibitor64

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIVLamivudinePhase 2Not yet recruitingThe University of Texas Health Science Center, HoustonOct 13, 2026
        A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)LamivudinePhase 2Not yet recruitingViiV HealthcareSep 11, 2026
        An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaLamivudinePhase 3Not yet recruitingUniversity College, LondonAug 28, 2026
        Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upLamivudinePhase 4RecruitingInstituto Mexicano del Seguro SocialJul 1, 2026
        Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIVLamivudinePhase 4Not yet recruitingUniversity of Witwatersrand, South AfricaJun 29, 2026
        Lamivudine as a Novel Clinical Effort for Rett SyndromeLamivudinePhase 2Enrolling by invitationMaria Denise Fernandes Carvalho de AndradeJun 10, 2026
        Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir RegimensLamivudinePhase 4Not yet recruitingShanghai Public Health Clinical CenterJun 8, 2026
        Dolutegravir/Lamivudine in Treatment-Naïve Pregnant WomenLamivudinePhase 4RecruitingFundación HuéspedJun 1, 2026

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363047, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.